Debon Securities released a research report on April 23 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and Q1 revenue increased 20% year over year; 2) the domestic release of cyclopofol was rapid, and internationalization progressed smoothly; 3) there are plenty of follow-up pipelines, and 12 Class 1 innovative drugs have entered the clinical stage, which ushered in the harvest period. (Mainichi Keizai Shimbun)
德邦证券4月23日发布研报称，给予海思科（002653.SZ）买入评级。评级理由主要包括：1）业绩符合预期，Q1收入同比增长20%；2）环泊酚国内放量迅速，国际化进展顺利；3）后续管线丰富，进入临床阶段的有12个1类创新药，迎来收获期。（每日经济新闻）
Debon Securities released a research report on April 23 stating that it gave HiCisco (002653.SZ) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and Q1 revenue increased 20% year over year; 2)
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.